The 4th International Forum （第4回国際交流フォーラム）

DAY1
Date: Friday, April 25, 2014
Place: Room 8（5F, Hall D5, Block D, Tokyo International Forum）

Opening Remarks
Tooru Shimosegawa (Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan)

I Drug-associated GI Injury: Advances of the pathogenesis and recent clinical topics
1. Advances of the pathogenesis
(a) Mucosal injury and prostaglandins (8:30～10:30)
Moderators: Jian-Ying Wang (University of Maryland School of Medicine, USA)
                      Koji Takeuchi (Kyoto Pharmaceutical University, Japan)
IFI-1a-1 RNA-binding protein HuR and microRNAs in gut epithelial homeostasis and diseases
                Jian-Ying Wang (University of Maryland School of Medicine, USA)
IFI-1a-2 Bile acid activated receptors regulates integrity of gastrointestinal mucosa
                Stefano Fiorucci (Department of Surgery and Biomedical Sciences, University of Perugia, Italy)
IFI-1a-3 Roles of prostanoids in the maintenance of gastric mucosal integrity and the healing of gastric ulcers
                Masataka Majima (Department of Pharmacology, Kitasato University School of Medicine, Japan)
IFI-1a-4 Identification of a unique NSAID, fluoro-loxoprofen with gastroprotective activity
                Tohru Mizushima (Faculty of Pharmacy, Keio University, Japan)
IFI-1a-5 Rescuing from NSAID-induced GI injury: PUFAs, SAC, and more
                Ki. Baik Hahm (CHA University School of Medicine and Cancer Prevention Research Center, Korea)

(b) Bacterial involvement (10:30～11:30)
Moderators: John L. Wallace (University of Calgary, Canada)
                      Toshifumi Ohkusa (Department of Gastroenterology and Hepatology, The Jikei University Kashiwa Hospital, Japan)
IFI-1b-1 The complicated role of bacteria in NSAID-induced enteropathy
                John L. Wallace (University of Calgary, Canada)
IFI-1b-2 NSAID enteropathy and intestinal bacteria: A review of Japanese studies
                Toshifumi Ohkusa (Department of Gastroenterology and Hepatology, The Jikei University Kashiwa Hospital, Japan)
IFI-1b-3 Importance of TLR4–dependent pathways for the pathogenesis and treatment of NSAID–induced enteropathy
Toshio Watanabe (Department of Gastroenterology, Osaka City University Graduate School of Medicine, Japan)

Best Short Oral Presentations (GI mucosal injury) (11:30～11:40)
Moderator: Neesa S. Abraham (Mayo School of Medicine, USA)
IFI-BSOP-1 PPI as the risk for small bowel injury who take continuous low–dose aspirin
Yasuhiro Komiya (Yokohama Rosai Hospital, Japan)
IFI-BSOP-2 Role of the TGF–β signaling inhibitor Smad7 in NSAIDs–induced gastric mucosal damage
Sung-Hun Kwon (CHA Cancer Prevention Research Center, CHA Cancer Institute, CHA University, Korea)

Short Oral Presentations (GI mucosal injury 1) (11:40～12:00)
Moderator: Angel Lanas (University of Zaragoza, Spain)
IF-SOP-1 Comparison of NSAIDs including aspirin induced mucosal injury in the entire gastrointestinal tract
Masayoshi Ono (Department of Gastroenterology, Hokkaido University Graduate School of Medicine, Japan)
IF-SOP-2 Effect of phosphatidylcholine (PC)–aspirin on small bowel mucosal injury
Xue Xiao (Department of Surgery, The Chinese University of Hong Kong, Hong Kong)
IF-SOP-3 The comparison of selective cyclooxygenase–2 inhibitor induced small bowel injury with loxoprofen: A randomized cross–over study in healthy subjects
Kazuhiro Mizukami (Department of Gastroenterology, Oita University, Japan)
IF-SOP-4 Association between small bowel mucosal injuries and history of medication in patients with obscure gastrointestinal bleeding
Takayuki Kato (Gastroenterology Division, Tokyo Metropolitan Hiroo Hospital, Japan)

I Drug–associated GI Injury: Advances of the pathogenesis and recent clinical topics
2. Recent clinical topics
(a) Antiplatelet therapy: Mucosal injuries and drug interaction with PPI (15:00～16:30)
Moderators: Angel Lanas (University of Zaragoza, Spain)
Mototsugu Kato (Division of Endoscopy, Hokkaido University Hospital, Japan)
IFI-2a-1 Management of low dose aspirin and clopidogrel in clinical practice – A GI perspective
Angel Lanas (University of Zaragoza, Spain)
IFI-2a-2 Event timing GI damages and eradication of H. pylori eradication in LDA user
Takashi Kawai (Endoscopy Center, Tokyo Medical University Hospital, Japan)
IFI-2a-3 Proton pump inhibitors and antiplatelet agents: Safe to prescribe together?
Neena S. Abraham (Department of Medicine, Division of Gastroenterology, Mayo Clinic College of Medicine, USA)
IFI-2a-4  Role of CYP2C19 in antiplatelet therapy and PPIs  
Takahisa Furuta (Center for Clinical Research, Hamamatsu University, Japan)

(b) **Bowel injuries (16:30~17:45)**

Moderators : Francis Ka–Leung Chan (Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong)
Tetsuo Arakawa (Osaka City University School of Medicine, Japan)

IFI-2b-1  Should aspirin be resumed in patients with a history of aspirin–related lower GI bleeding?  
Francis K.L. Chan (Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong)

IFI-2b-2  Small bowel injury in low–dose aspirin users  
Hiroki Endo (Department of Gastroenterology, Yokohama City University Hospital, Japan)

IFI-2b-3  A randomized, double–blinded, placebo–controlled, multicenter trial, healing effect of rebamipide in patients with low–dose aspirin and/or non–steroidal anti–inflammatory drug induced small bowel injury  
Sei Kurokawa (Department of Gastroenterology, Sapporo–Kosei General Hospital, Japan)

IFI-2b-4  Strategy of NSAID–induced small bowel lesions  
Kazuhide Higuchi (Second Department of Internal Medicine, Osaka Medical College, Japan)

**Short Oral Presentations (GI mucosal injury 2) (17:45~18:05)**

Moderator : Francis Ka–Leung Chan (Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong)

IFI-SOP-5  Low–dose aspirin–associated gastric and duodenal ulcers in Japanese patients with no previous history of peptic ulceration  
Atsushi Tanabe (Department of Gastroenterology, Aichi Medical University School of Medicine, Japan)

IFI-SOP-6  The protective role of genistein on gastric mucosal lesion induced by paracetamol  
Syifa Mustika (Gastroenterohepatology Division, Internal Medicine Department, Faculty of Medicine, Brawijaya University, Indonesia)

IFI-SOP-7  Esophageal mucosal injury and symptoms in elderly persons taking low dose aspirin  
Yuji Shimada (Department of Gastroenterology, Juntendo University School of Medicine, Japan)

IFI-SOP-8  Prevention of *Helicobacter pylori*–induced gastritis and carcinogenesis with daily intake of specially formulated Korean kimchi  
Mi–Kyoung Jung (CHA Cancer Prevention Research Center, CHA Cancer Institute, CHA University, Korea)
II Challenge to the pancreatic and biliary cancers

1. Pancreatic and biliary cancers—Challenge to the pathogenesis (8:30~9:45)

Moderators: Ralph H. Hruban (The Johns Hopkins University, USA)
Toru Furukawa (Tokyo Women’s Medical University, Japan)

IFII-1-1 The molecular classification of pancreatic neoplasia
   Ralph H. Hruban (The Johns Hopkins University School of Medicine, USA)

IFII-1-2 Pathology of bile duct carcinoma with emphasis on pre-invasive lesions
   Yasuni Nakanuma (Department of Human Pathology, Kanazawa University
   Graduate School of Medicine / Department of Pathology, Shizuoka Cancer Center, Japan)

IFII-1-3 Significance of CXC Chemokines/CXCR2 Axis in Pancreatic Cancer Progression
   Hideaki Iijichi (Department of Gastroenterology, The University of Tokyo, Japan)

IFII-1-4 Involvement of epithelial to mesenchymal transition and its related molecules in
   the development of pancreatic ductal adenocarcinoma
   Kennichi Satoh (Division of Cancer Stem Cell Miyagi Cancer Center Research
   Institute, Japan)

2. Pancreatic cancer—Challenge to the early detection (9:45~10:45)

Moderators: Howard A. Reber (Department of Surgery, UCLA School of Medicine, USA)
Masao Tanaka (Kyushu University, Japan)

IFII-2-1 Detecting early pancreatic cancer—Problems and prospects
   Suresh T. Chari (Division of Gastroenterology and Hepatology, Department of
   Internal Medicine, Mayo Clinic College of Medicine, USA)

IFII-2-2 Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal
   adenocarcinoma concomitant with IPMN
   Koji Yamaguchi (Department of Surgery 1, University of Occupational and
   Environmental Health, Japan)

IFII-2-3 Diagnostic strategies for the early diagnosis of pancreatic cancer
   Keiji Hanada (Department of Gastroenterology, Onomichi General Hospital,
   Japan)

Best Short Oral Presentations (Pancreaticobiliary disorders) (10:45~10:55)

Moderator: Nobuyuki Enomoto (First Department of Internal Medicine, University of Yamanashi,
Japan)

IFII-BSOP-1 Loss of E-cadherin in the liver induces sclerosing cholangitis and promotes
   hepatocarcinogenesis
   Hayato Nakagawa (Department of Gastroenterology, The University of
   Tokyo, Japan)
Short Oral Presentations (Pancreaticobiliary disorders 1) (10:55~11:30)

Moderator: Suresh T. Chari (Department of Medicine, Mayo Clinic College of Medicine, USA)

IF-SOP-9 Which has a higher risk for developing pancreatic cancer, autoimmune pancreatitis or ordinary chronic pancreatitis?
Tsukasa Ikeura (The Third Department of Internal Medicine, Kansai Medical University, Japan)

IF-SOP-10 Challenge to early detection of pancreatic ductal adenocarcinoma focused on surveillance of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
Koji Tamura (Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Japan)

IF-SOP-11 Etomidate with meperidine vs midazolam with meperidine for sedation during Endoscopic Retrograde Cholangiopancreaticography (ERCP)
Byung Hyo Cha (Digestive Disease Center and Department of Internal Medicine, Cheju Halla General Hospital, Korea)

IF-SOP-12 The role of gastrodeuodenal stent intervention in the treatment of pancreatic cancers
Takamitsu Sato (Department of Gastroenterology, Aichi Cancer Center Hospital, Japan)

IF-SOP-13 Predictors of failed stenting during Endoscopic Retrograde Cholangiopancreatography (ERCP) in malignant biliary obstruction
Michael V. Chu (East Avenue Medical Center, Section of Gastroenterology, Philippines)

IF-SOP-14 A retrospective analysis comparing the treatment outcomes of gemcitabine and S-1 combination therapy to gemcitabine and cisplatin combination therapy in patients with advanced biliary tract cancer
Takashi Sasaki (Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan)

IF-SOP-15 Combination of human equilibrative nucleoside transporter 1 and thymidylate synthase expression could predict prognosis after surgery in the locally advanced cholangiocarcinoma patients treated with NAC with gemcitabine and S-1
Yasuhiro Yabushita (Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Japan)
3. Pancreatic cancer—Challenge to the better treatment (13:10~14:40)

Moderators: Suresh T. Chari (Department of Medicine, Mayo Clinic College of Medicine, USA)
Akimasa Nakao (Nagoya Central Hospital, Japan)

IFII-3-1 Downstaging of locally advanced pancreatic adenocarcinoma with prolonged neoadjuvant therapy
Howard A. Reber (David Geffen School of Medicine at UCLA, USA)

IFII-3-2 Multimodality therapy for borderline resectable pancreatic cancer: Is neoadjuvant chemoradiation necessary?
Vincent J. Picozzi (Digestive Disease Institute, Virginia Mason Medical Center, USA)

IFII-3-3 Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for borderline resectable pancreas body cancer
Hiroki Yamaue (Second Department of Surgery, Wakayama Medical University, Japan)

IFII-3-4 Preoperative chemoradiotherapy for borderline resectable pancreatic ductal adenocarcinoma
Shuji Isaji (Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University, Japan)

4. Biliary cancer—Challenge to the better prognosis (14:40~15:55)

Moderators: Peter Josef Neuhaus (Clinic for General, Visceral and Transplantation Surgery, Charité–Universitätsmedizin Berlin/Campus Virchow Clinic, Germany)
Michiaki Unno (Tohoku University, Japan)

IFII-4-1 Surgery of hilar and extrahepatic cholangiocarcinoma
Peter Neuhaus (Department of General–, Visceral– and Transplantation– Surgery, Charité–Universitätsmedizin Berlin Campus Virchow Klinikum, Germany)

IFII-4-2 How to manage the preoperative obstructive jaundice in biliary cancers?
Takao Ito (Department of Gastroenterology and Hepatology, Tokyo Medical University, Japan)

IFII-4-3 Pancreatico-biliary maljunction and biliary cancer
Terumi Kamisawa (Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital, Japan)

IFII-4-4 Aggressive surgical approach for perihilar cholangiocarcinoma
Masato Nagino (Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Japan)

Short Oral Presentations (Pancreatico-biliary disorders 2) (15:55~16:20)

Moderator: Ralph H. Hruban (Pathology and Oncology, Johns Hopkins University, USA)

IF-SOP-16 Is the WHO 2010 classification sufficient to clearly characterize pancreatic neuroendocrine carcinoma?
Susumu Hijioka (Department of Gastroenterology, Aichi Cancer Center Hospital, Japan)
IF-SOP-17  Pancreatic Ductal Adenocarcinoma (PDAC): Identification of compounds that inhibit NUPR1 protein function in cell culture
   Olga Abian (Aragon Health Science Institute, Spain)
IF-SOP-18  Loss of runt-related transcription factor 3 induces gemcitabine resistance via increasing the expression of multidrug resistant protein in pancreatic cancer
   Shigeru Horiguchi (Department of Gastroenterology & Hepatology, Okayama University Graduate School of Medicine, Japan)
IF-SOP-19  Mutant GNAS detected in duodenal collections of secretin–stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts
   Mitsuro Kanda (Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Japan)
IF-SOP-20  Investigation of biological characteristics of biliary tract cancers to establish a novel molecular–targeted therapy
   Masaaki Yokoyama (Kyorin University, Japan)

Closing Remarks
   Seiji Kawasaki (Department of Hepatobiliary Pancreatic Surgery, Juntendo University Graduate School of Medicine, Japan)